DrugAlert provides timely advice direct to your inbox and is based on information from drug manufacturers regarding critical changes to medication access such as the discontinuation, short supply or unavailability, recalls and other important drug-related information. See below to view the most recent volumes of DrugAlert.
HPS Pharmacies wish to advise that Pfizer has discontinued Hyoscine Hydrobromide ampoules as follows: DBL™ Hyoscine Hydrobromide Ampoules Hyoscine Hydrobromide 400 mcg/1mL ARTG 16347 There is currently not an Australian-registered product that is a…
Read more
HPS Pharmacies wish to advise that Pfizer is experiencing a supply interruption for Bicillin® L-A as follows: Bicillin L-A Benzathine benzylpenicillin tetrahydrate 1,200,000 Units / 2.3 mL ARTG 147169 Bicillin L-A Benzathine benzylpenicillin tetrahydrate…
Read more
HPS Pharmacies wish to give notice that Boehringer Ingelheim, in consultation with the Therapeutic Goods Administration (TGA), has issued a product defect correction for Spiriva® Respimat®, as follows: Spiriva Respimat Solution for Inhalation Tiotropium…
Read more
HPS Pharmacies wishes to advise that Victorian access to COVID therapies on the National Medication Stockpile (NMS) is coming to an end in April 2024. COVID therapies held by the NMS have the following…
Read more
HPS Pharmacies wishes to give notice that Merck Sharp & Dohme are continuing to experience a supply interruption for OncoTICE® as follows: OncoTICE Bladder Instillation Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain) ARTG…
Read more
HPS Pharmacies wish to give notice that Novo Nordisk, in consultation with the Therapeutic Goods Administration (TGA), has issued an urgent product defect alert for multiple batches of the following insulin products: Product Presentation…
Read more
